Skip to content
Contact us
Oncology Splash
oncology market research & commercial insights
 

Oncology Market Research &
Commercial Intelligence for Pharma.

With 250+ brands competing for oncologist attention and new mechanisms reshaping the landscape every congress cycle, generic market research leaves too much on the table. ZoomRx gives oncology brand teams the speed, depth, and precision to stay ahead.
Talk to an Oncology Research Specialist

Why Generic Market Research Misses the Mark in Oncology 

Promotional messages go live unvalidated

Most brands don’t know whether their core messages land with oncologists until after launch — when changing course is expensive.

Congress readouts shift intent overnight

A single ASCO or ESMO presentation can move prescribing intent before your brand team has even landed home. Most research cycles aren’t built to keep pace.

Sales rep interactions are underoptimized

Oncologists are the most time-constrained HCPs in pharma. A rep interaction that leads with the wrong content doesn’t get a second chance.

HCP perception gaps surface too late

By the time brand teams see a perception problem in Rx data, they’ve already lost months of momentum. The gap between what oncologists think and what your team assumes is wider than it looks.

Oncology Research That Drives Your Next Decision, Not Just Your Next Report

Every ZoomRx oncology program is built around one question: what does your brand team need to do next? From prelaunch positioning through post-launch optimization, we connect market insight to commercial action.

Brand Tracking (ATU)

Continuous HCP and patient tracking that goes beyond KPIs to actions — surfacing the shifts in awareness, perception, and trial that tell your team what to do next, not just what happened.

Explore
Promotional Effectiveness Tracking (PET)
Fully custom research tailored to your brand, indication, and field team — not an off-the-shelf tracker applied to your data. Built around what your specific HCPs respond to, benchmarked against real oncology norms.

 

explore
Pre-Launch & Launch Intelligence
Structured research from late Phase II through launch — covering HCP targeting, unmet needs, message development, and competitive positioning — so your brand enters the market with clarity, not assumptions.

 

explore
HCP-Patient Conversations

HIPAA-compliant exam-room research. 1,400+ transcripts delivered. Captures authentic clinical dialogue and integrates with ATU and PET.

Explore
Ferma
Real-time ASCO, ASH, ESMO coverage. AI-generated session summaries. ZoomRx has run its post-ASCO oncologist survey annually since 2019.

 

explore
Digital & Media tracking
Passive, person-level tracking across banner ads, email, search, and medical platforms. Verified oncologist-level data — no household proxies.

 

explore
Patient Chart Audits (PCA)
Voice-first AI for patient charts. Captures treatment decision rationale and patient journey drivers without compromising HCP experience.

 

explore
INDICATIONS
Breast Cancer NSCLC Multiple Myeloma CLL Prostate Cancer GI Cancers Hematologic Malignancies Rare Cancers

What Makes ZoomRx Different in Oncology

Onc-Icon 1
Insight you can act on, not just report on
 
ZoomRx doesn’t hand you a dashboard — we tell your team what the data means and what to do next. Every wave, every study, every congress readout is framed around your next commercial decision.
Onc-Icon 2
Custom research, not a syndicated tracker applied to your brand
 
Every ZoomRx oncology program is built around your specific HCPs, your indication, and your competitive set. That’s why brands switch to ZoomRx — and stay.
Onc-Icon 3
One team holds the full picture across your brand lifecycle
 
Pre-launch insight, brand tracking, promotional effectiveness, and patient research in one connected workflow. No fragmentation, no lost context between vendors.
Onc-Icon 4
AI that makes your research faster and sharper, not generic
 
Ferma surfaces what changed at ASCO, ASH, and ESMO before your team lands home. Message Labs tells you which messages will work before you deploy them. Human experts tell you what it means for your brand.
Onc-Icon 5
Oncology depth built on 80+ launches, not borrowed from other TAs
 
ZoomRx’s benchmarks come from real oncology research — across your indication, your launch stage, and your competitive context. Not cross-TA averages.

Quote-Icon

We went into launch with a clearer picture of where oncologists stood than any brand I'd worked on before. ZoomRx gave us the HCP perception data we needed to make the right call on messaging before we were in the market — not after.

User Icon
Senior Director, Commercial Insights
Top 10 Biopharma

Explore Other Therapeutic Areas

ZoomRx delivers pharma market research across multiple therapeutic areas. Explore our research and capabilities by TA.
Metabolic

GLP-1s, diabetes, obesity — the fastest-growing TA in pharma. ZoomRx tracks brand dynamics, HCP adoption, and competitive intelligence across metabolic indications. 

Explore
CNS
Neurology, psychiatry, and rare neurological conditions. ZoomRx supports pre-launch intelligence and brand tracking across the full CNS indication landscape.

 

explore

Oncology Research from ZoomRx

Primary research conducted with practicing oncologists and hem-oncologists — not secondary data compilation.
Oncology (1)
Oncology Manufacturer Perception Report — Q2 2025
read more
ASCO conference
ASCO 2025: ZoomRx 7th Annual Oncologist Survey
read more
FiercePharmaArticle
Enhertu, Keytruda Lead Oncology HCP Marketing — Fierce Pharma
read more

CTA

Talk to an Oncology Research Specialist

Tell us about your brand and research challenge. We'll connect you with a ZoomRx oncology specialist who has worked across your indication, your competitive set, and your launch stage.

Get in touch

Frequently Asked Questions

Which cancer types receive the most pharma promotional attention?

Breast cancer, non-small cell lung cancer (NSCLC), multiple myeloma, chronic lymphocytic leukemia (CLL), and prostate cancer — in that order. ZoomRx's analysis of 71,000+ HCP interactions between July 2024 and June 2025 found these five indications account for 49% of all oncology promotions, with the top 10 pharma companies responsible for approximately two-thirds of total oncology HCP promotional activity.

How do you choose an oncology market research partner?

Look for a partner with oncology-specific benchmarks built from real indication data, custom research tailored to your brand rather than a syndicated tracker, and one team covering HCP and patient research in a single workflow. ZoomRx is built for exactly this, with a benchmark database of 3,000+ oncology messages across 115+ brands and primary research spanning 40+ indications.

What oncology indications does ZoomRx have the most research depth in?

ZoomRx's research has the deepest coverage in the five indications that dominate oncology promotional activity: breast cancer (including HER2+, HER2-Low, and TNBC), non-small cell lung cancer, multiple myeloma, chronic lymphocytic leukemia, and prostate cancer. ZoomRx also covers emerging indications including glioma and metastatic pancreatic cancer, which oncologists in 2025 identified as the areas with the highest unmet clinical need.